（文章来源：证券日报） 证券日报网讯 8月21日晚间，光正眼科发布公告称，公司第六届监事会第五次会议审议通过了《关于工 商变更企业类型并修订的议案》等多项议案。 ...

Group 1 - The company, Guangzheng Eye Hospital (002524.SZ), reported a revenue of 436 million yuan for the first half of the year, representing a year-on-year decline of 9.49% [1] - The net profit attributable to shareholders of the listed company was 1.4189 million yuan, showing a year-on-year increase of 11.38% [1] - The company experienced a non-recurring net loss of 3.2798 million yuan [1]

天眼查显示，近日，厦门思明星光灼灼眼科诊所有限公司成立，法定代表人为林水龙，注册资本250万 人民币，由厦门星光卓越医疗管理有限公司全资持股。 经营范围含诊所服务；眼镜销售（不含隐形眼镜）；眼镜制造；第一类医疗器械销售；第二类医疗器械 销售；光学仪器销售；电子专用材料销售；功能玻璃和新型光学材料销售；健康咨询服务（不含诊疗服 务）；保健食品（预包装）销售。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）许 可项目：医疗服务；第三类医疗器械经营。（依法须经批准的项目，经相关部门批准后方可开展经营活 动，具体经营项目以相关部门批准文件或许可证件为准）。 企业名称厦门思明星光灼灼眼科诊所有限公司法定代表人林水龙注册资本250万人民币国标行业卫生和 社会工作>卫生>医院地址厦门市思明区吕岭路1583号宝龙一城一期1-6号楼第L2层S1-L2-002之二企业类 型有限责任公司（自然人投资或控股的法人独资）营业期限2025-8-20至无固定期限登记机关 来源：金融界 序号股东名称持股比例1厦门星光卓越医疗管理有限公司100% ...

Core Points - The company, Guangzheng Eye Hospital Group Co., Ltd., has announced a supplementary notice regarding the second extraordinary general meeting of shareholders for the year 2025, scheduled for September 4, 2025 [1][2] - The controlling shareholder, Guangzheng Investment Co., Ltd., will submit a temporary proposal to amend the company's articles of association at the upcoming meeting [1][2] - The meeting will allow shareholders to vote either in person or via an online voting platform provided by the Shenzhen Stock Exchange [2][5] Meeting Details - The extraordinary general meeting will take place on September 4, 2025, at 15:00, with online voting available from 9:15 to 11:30 on the same day [2][3] - Shareholders must register to attend the meeting, with specific procedures outlined for both individual and corporate shareholders [3][4] - Voting will be conducted through a single method, either in-person or online, and duplicate votes will be disregarded, with the first valid vote counted [3][6] Proposals for Discussion - The agenda includes a proposal for the repurchase and cancellation of part of the restricted stock incentive plan from 2023, which has already been approved by the company's supervisory board [3][8] - Another proposal involves changing the company's business type and amending the articles of association, which will also be presented for approval [8]

Core Viewpoint - The company reported a decline in operating revenue for the first half of 2025, while net profit showed an increase, indicating mixed financial performance [1] Financial Performance - Operating revenue for the first half of 2025 was 436 million yuan, representing a year-on-year decrease of 9.49% [1] - Net profit for the same period was 1.4189 million yuan, reflecting a year-on-year increase of 11.38% [1]

Group 1 - The stock price of Aier Eye Hospital closed at 13.24 yuan on August 20, 2025, reflecting a 1.22% increase from the previous trading day, with a trading volume of 1.389 billion yuan and a fluctuation of 2.52% [1] - Aier Eye Hospital is a leading ophthalmology medical chain in China, offering services in refractive surgery, cataract treatment, and vision care [1] - The Shanghai Aier Eye Hospital has introduced a plasma coating care technology that can repair scratched corneal reshaping lenses (OK lenses), effectively reducing the cost for parents to replace lenses. This technology cleans the lens surface using low-temperature argon plasma, achieving a sterilization rate of over 90%, and has already helped over a hundred children extend the lifespan of their lenses in outpatient settings [1] Group 2 - On August 20, Aier Eye Hospital saw a net inflow of 23.5613 million yuan in main funds, while there was a net outflow of 1.79 billion yuan over the past five days [2]

Core Viewpoint - He Eye Hospital's stock price reached 23.78 yuan as of August 18, 2025, reflecting a 1.28% increase from the previous trading day [1] Company Summary - He Eye Hospital operates in the medical services sector, focusing on ophthalmology, optometry services, and eye health management [1] - The stock opened at 23.60 yuan, peaked at 23.96 yuan, and dipped to a low of 23.49 yuan on the same day [1] - The trading volume was 24,947 hands, with a total transaction value of 0.59 billion yuan [1] Financial Flow Summary - On August 18, the net outflow of main funds was 35.69 thousand yuan, accounting for 0.02% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 713.40 thousand yuan, representing 0.36% of the circulating market value [1]

Core Viewpoint - The company, Aier Eye Hospital, highlights the low awareness and acceptance of presbyopia treatment among the elderly population in China, contrasting it with the higher acceptance in Europe, indicating a significant growth opportunity in the domestic market [2] Group 1: Market Awareness and Demand - A majority of middle-aged and elderly individuals in China have a low understanding of presbyopia treatment, resulting in a very low penetration rate of such treatments in the country [2] - In contrast, European regions show a higher acceptance of presbyopia treatment, with the company's European subsidiary having a wealth of experience and a well-developed presbyopia surgery business [2] Group 2: Strategic Initiatives - To address the growing demand due to an aging population, the company is leveraging overseas team experiences to actively develop services related to elderly eye disease diagnosis and presbyopia treatment [2] - The company has opened presbyopia clinics in multiple locations and plans to establish a presbyopia study group to provide suitable visual solutions for the elderly population [2] Group 3: Future Growth Potential - With the increasing payment capability of the target demographic and their pursuit of better visual quality, the presbyopia treatment market is expected to see sustained growth in the future [2]

公司回答表示：谢谢您对公司的关注。目前国内大多数中老年人对老花（老视）治疗的认知程度不高， 老花治疗在国内普及率极低，还处于启蒙阶段。 与之对应的是，欧洲地区对老花治疗的接受度较高， 公司的欧洲子公司经验丰富，老花手术业务发展良好。 为了适应人口老龄化背景下的大量新需求，公 司结合海外团队经验积极发展老年眼病诊断、老视治疗等业务，已在多地爱尔医院开设老视门诊，并将 成立老视学组，为广大中老年人群提供适宜的视觉解决方案。 随着适龄段人群支付能力的提高和对视 觉品质的追求，老花诊疗未来有望持续增长。责任编辑：磐石 金融界8月18日消息，有投资者在互动平台向爱尔眼科提问：董秘你好，目前我们人口老龄化一直在加 剧，老年人口越来越多，但是目前针对老年人的视力矫正并不普及，很多人觉得老花眼没办法治疗，这 个对公司的未来业务增长相当重要，公司有没有关注到这方面的潜在需求，在这方面有没有相关的技术 储备，公司的技术储备在国际上处于什么样的水平。 ...

Core Viewpoint - The article discusses common misconceptions about myopia prevention and treatment in children, emphasizing the importance of accurate eye examinations and appropriate corrective measures. Group 1: Eye Examination Methods - Cycloplegic refraction is a standard method for assessing children's refractive errors, temporarily paralyzing the ciliary muscle to obtain accurate measurements [1] - Quick cycloplegia is suitable for children over 8 years old, using a combination of tropicamide eye drops, with a fast recovery time [1] - Slow cycloplegia, using 1% atropine ointment, is recommended for younger children, providing more accurate results but with a longer recovery time of about three weeks [1] Group 2: Myopia Treatment Guidelines - Children with myopia between 50-300 degrees may not need glasses if their naked eye vision is acceptable (0.8 or above) and they do not experience significant eye strain [2] - For moderate myopia (300-600 degrees) and high myopia (over 600 degrees), it is advised to wear corrective glasses all day to prevent further eye strain and elongation of the eyeball [2] Group 3: Importance of Regular Check-ups - Regular follow-ups every three months are essential after getting glasses to monitor changes in vision and eye axis length, allowing for timely adjustments in myopia management strategies [3] Group 4: Other Common Eye Conditions - Besides myopia, conditions like amblyopia, astigmatism, and strabismus are prevalent in children and require attention [4] - Amblyopia, if not treated by age 6-8, can lead to permanent vision impairment [5] - Astigmatism is often congenital and can be corrected through glasses or contact lenses [6] - Strabismus requires professional evaluation to determine the cause and severity for personalized treatment [7] Group 5: Myopia Prevention Misconceptions - Wearing glasses does not cause eye deformation; they are external aids and do not affect the eye's development [8] - Low-concentration atropine eye drops can slow myopia progression but cannot reverse it [9] - Corrective lenses should match the child's actual refractive error; under-correcting can lead to increased eye strain and worsen myopia [10] - Wearing appropriate glasses does not worsen myopia; in fact, not wearing them can accelerate its progression [11]